Table 3:

Comparison of Ocular Staining Score (OSS) score by novel autoantibody status at baseline in the Penn Sjogren’s International Clinical Collaborative Alliance (SICCA) Study Participants without Sjogren’s Syndrome (n=129)

Novel antibody	Novel Antibody Absence		Novel Antibody Presence
	n	Mean (SD)	n	Mean (SD)	P-value
Salivary protein 1 (SP-1)
IgG	123	4.8 (3.0)	6	4.5 (1.4)	0.79
IgA	125	4.8 (2.9)	4	5.5 (2.9)	0.63
IgM	123	4.7 (3.0)	6	6.7 (1.6)	0.11
Any	113	4.7 (3.0)	16	5.6 (2.0)	0.27
Carbonic anhydrase 6 (CA-6)
IgG	121	4.8 (2.9)	8	4.4 (3.3)	0.67
IgA	120	4.8 (2.9)	9	4.8 (3.5)	0.98
IgM	117	4.7 (2.9)	12	5.7 (3.3)	0.29
Any	103	4.8 (2.9)	26	4.8 (3.1)	0.94
Parotid specific protein (PSP)
IgG	123	4.7 (2.9)	6	6.8 (2.3)	0.08
IgA	115	4.9 (2.9)	14	3.8 (2.8)	0.17
IgM	118	4.7 (2.9)	11	6.0 (3.4)	0.16
Any	102	4.8 (2.9)	27	4.8 (3.0)	0.96
Any novel antibody	83	4.9 (3.0)	46	4.7 (2.9)	0.75
Number of novel antibodies positive
0	83	4.8 (3.0)
1	24	4.1 (2.9)
2–3*	22	5.4 (2.8)
	P=0.32 (any difference) P=0.69 for linear trend test

^*Only 1 patient had a value of 3.